Wang, W <br/><br/>
Specificity redirection by CAR with human VEGFR-1 affinity endows T lymphocytes with tumor-killing ability and anti-angiogenic potency.  [electronic resource] 

 -  Gene therapy  Oct 2013 
 - 970-8 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1476-5462 
<br/><br/><label>Standard No.: </label>10.1038/gt.2013.19  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antigens, Neoplasm--immunology<br/>Cell Death<br/>Cells, Cultured<br/>Cytotoxicity, Immunologic<br/>Electroporation<br/>Genetic Therapy--methods<br/>HeLa Cells<br/>Humans<br/>Immunotherapy, Adoptive<br/>Mice<br/>Mice, SCID<br/>Neoplasms, Experimental--immunology<br/>Receptors, Antigen, T-Cell--immunology<br/>Recombinant Fusion Proteins--immunology<br/>T-Cell Antigen Receptor Specificity<br/>T-Lymphocytes--immunology<br/>Vascular Endothelial Growth Factor Receptor-1--immunology<br/>Xenograft Model Antitumor Assays